Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Metabolife 356 “Unreasonably Dangerous,” Jury Says In $4.1 Mil. Verdict

This article was originally published in The Tan Sheet

Executive Summary

Metabolife sold its ephedrine alkaloid-containing Metabolife 356 in a "defective condition unreasonably dangerous to an ultimate user," a Birmingham, Ala. federal jury concluded in four cases Nov. 19

You may also be interested in...



Metabolife Liability Reversal Offers Precedent For Ephedra Defendants

Defendants' prospects in future ephedra liability suits may have been strengthened by a FDL-1federal appeals court reversal of a $4.1 mil. jury award against Metabolife

Metabolife Liability Reversal Offers Precedent For Ephedra Defendants

Defendants' prospects in future ephedra liability suits may have been strengthened by a FDL-1federal appeals court reversal of a $4.1 mil. jury award against Metabolife

Metabolife Liability Reversal Offers Precedent For Ephedra Defendants

Defendants' prospects in future ephedra liability suits may have been strengthened by a FDL-1federal appeals court reversal of a $4.1 mil. jury award against Metabolife

Related Content

Topics

UsernamePublicRestriction

Register

PS094825

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel